Chief Medical Officer and Senior Vice President · CRESCENT BIOPHARMA, INC. (CBIO)

Edwin Rock

FY2023 is the first fiscal year CompBrief holds for Edwin Rock as a named executive officer of CRESCENT BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,152,311

Salary $466,620Stock awards $0

3rd of 3 named executive officers at Crescent Biopharma by FY2023 total.

3 named officers on file for CRESCENT BIOPHARMA, FY2023

Edwin Rock’s pay file — $29

  • 1 fiscal year of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 1, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Edwin Rock’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Edwin Rock compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$466,620
Bonus$0
Stock awards$0
Option awards$474,912
Non-equity incentive$198,779
Pension and deferred compensation$0
All other$12,000
Total$1,152,311

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 1, 2024, accession 0001558370-24-004448, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-24-004448. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option137,500—$0.74
Option244,800—$2.55

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2023 proxy (filed April 1, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-06-21Purchase—115,000$0.27680,403
2024-06-20Purchase—190,000$0.25565,403

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CRESCENT BIOPHARMA’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Harout SemerjianPresident and Chief Executive Officer$2,389,418
Brian HahnChief Financial Officer and Senior Vice President$1,299,939
Edwin Rock · this pageChief Medical Officer and Senior Vice President$1,152,311

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Edwin Rock's compensation dossier · One-time report. No refunds.